Intellia Therapeutics Inc.

In News

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics

Intellia Therapeutics - Feb 26, 2026

Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA) - Seeking Alpha

Seeking Alpha - Mar 09, 2026

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data - Sahm

Sahm - Mar 08, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

GlobeNewswire - Mar 06, 2026

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory - Yahoo Finance

Yahoo Finance - Feb 28, 2026

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Revista ADVFN

Revista ADVFN - Mar 06, 2026

FDA ends trial halt on 1,200-patient heart disease study - Stock Titan

Stock Titan - Mar 02, 2026

Intellia Therapeutics to Participate in Upcoming Investor Conferences - Intellia Therapeutics

Intellia Therapeutics - Feb 24, 2026

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Yahoo Finance - Feb 26, 2026

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates - Intellia Therapeutics

Intellia Therapeutics - Nov 06, 2025

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics

Intellia Therapeutics - Jan 07, 2026

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics

Intellia Therapeutics - Oct 27, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment